Broken String’s Next Generation Sequencing (NGS)-based DNA break mapping platform, INDUCE-seq, will offer researchers working on cell and gene therapies the opportunity to speed up analysis of how genome editors interact with and alter human genomes. Providing researchers with this information earlier in the drug development process will help reduce the chance of clinical failures during testing at later phases.

Broken String Biosciences was founded by Professor Simon Reed, a specialist in cancer studies at the Cardiff University School of Medicine, and two Early Career Researchers, Felix Dobbs and Patrick van Eijk. Spun out in 2020, the company completed a six-month residency at the Illumina Accelerator in Cambridge, UK, and closed a Series Seed financing of around $4m USD with investors from the UK, Germany and the US in September 2021. In 2023, the company closed a successful $15m USD funding round to support future growth.